Loading stock data…
ARMP
$8.89-1.09 (-10.92%)
Market ClosedLast close May 1
Armata Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Armata Pharmaceuticals, Inc. in the Healthcare sector is trading at $8.89. The stock is currently 46% below its 52-week high of $16.34, remaining 41.1% above its 200-day moving average. Technical signals show neutral RSI of 39 and bearish MACD signal, explaining why ARMP maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 39) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$8.89
Potential Upside
5%
Whystock Fair Value$9.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacte...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$509.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.94%
Volume
Today's trading volume
56,326
Recent News
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod
Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the most promising stocks. On February 23, 2026, H.C. Wainwright increased the price target for ARMP from $9.00 to $15.00 and kept a Buy rating on the shares. The modification comes after […]
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?